



**FOR IMMEDIATE RELEASE**

## **Affimed to Present at Noble Financial Capital Markets' 12<sup>th</sup> Annual Investor Conference**

*Heidelberg, Germany, January 12, 2016* - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CFO, Florian Fischer, will present at the NobleCon12 - Noble Financial Capital Markets' 12th Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19 at 11:30 am Eastern Standard Time.

Following the conference on January 22, 2016, a high-definition video webcast of Affimed's presentation and a copy of the presentation materials will be available on the Company's website, [www.affimed.com](http://www.affimed.com), or as part of a complete catalog of presentations available on the Noble Financial websites: [www.noblefcm.com](http://www.noblefcm.com), or [www.nobleconference.com](http://www.nobleconference.com). A Microsoft SilverLight viewer (a free download from the presentation link) will be required to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit [www.affimed.com](http://www.affimed.com).

## **FORWARD-LOOKING STATEMENTS**

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

### **Contact:**

Affimed N.V.

Caroline Stewart, Head IR & Communication

Phone: +1 347394 6793

E-Mail: [IR@affimed.com](mailto:IR@affimed.com) or [c.stewart@affimed.com](mailto:c.stewart@affimed.com)

### **Media requests:**

Stephanie May or Gretchen Schweitzer

MacDougall Biomedical Communications

Phone: +49 89 2424 3494 or

+49 172 861 8540

E-Mail: [gschweitzer@macbiocom.com](mailto:gschweitzer@macbiocom.com)